Daraxonrasib: New Hope, New Questions for Pancreatic Cancer

Tori Larrick, Associate Director of Patient Services at PanCAN, joined Living Hope: Your Journey with Pancreatic Cancer to discuss the growing excitement surrounding daraxonrasib, what emerging treatments may mean for patients, how patients can advocate for themselves and explore treatment options, and the emotional impact of hearing about promising advances that may not yet be accessible to everyone. It’s an important conversation about hope, access, advocacy, and empowering patients with trusted information. **Since this episode aired, there has been an important development: On August 26, 2026, the FDA approved daraxonrasib, under the brand name Rasonque, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, as well as certain patients who are not candidates for multiagent systemic therapy.